Skip to main content

Table 2 Findings of bronchoalveolar lavage analysis

From: Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer

Case

Age

Gender

Smoking status

Site

Recovery rate (%)

TCC (× 105/mL)

AM (%)

Lym (%)

Neu (%)

Eos (%)

CD4:CD8

1

68

M

Former

2

73

F

Never

rt. B10

49.0

2.1

52.6

44.8

1.8

0.8

1.5

3

68

M

Former

rt. middle lobe

59.5

1.6

47.0

46.4

5.8

0.8

0.3

4

66

M

Former

lt. B5

58.0

2.7

66.4

29.0

1.6

3.0

0.5

5

51

M

Current

rt. B5

59.0

2.2

5.8

90.4

0.8

3.0

0.5

6

79

M

Former

lt. B4

49.0

1.3

12.2

86.0

1.4

0.4

0.9

7

70

M

Former

lt. B8

43.5

2.5

20.4

76.6

1.4

1.6

3.6

8

74

M

Former

rt. B3

17.5

0.4

32.2

47.8

15.6

4.4

0.5

9

72

M

Former

10

71

M

Former

rt. B4

57.0

3.5

54.0

30.0

14.0

2.0

0.1

11

63

F

Never

rt. B4

70.2

2.3

16.2

64.2

0.4

19.2

0.5

12

70

F

Never

rt. B2

41.5

1.2

78.8

20.4

0.4

0.4

0.5

  1. Cases 1–5, 7, 8, 12: adenocarcinoma; Cases 6, 9, 11: squamous cell carcinoma; Case 10: not otherwise specified
  2. AM, alveolar macrophage; CD, cluster of differentiation; Eos, eosinophils; Lym, lymphocytes; Neu, neutrophils; TCC, total cell count